Indeed, 17 HCC patients at a noncirrhotic stage were included in this study (Table 1), which suggested a risk difference among KIR/HLA genotypes between liver cirrhosis patients and noncirrhotic patients. This evidence concerns the gene KIR3DL1 and hepatocellular carcinoma.